Anti-tumor effect of estrogen-related receptor alpha knockdown on uterine endometrial cancer

Hiroshi Matsushima; Taisuke Mori; Fumitake Ito; Takuro Yamamoto; Makoto Akiyama; Tetsuya Kokabu; Kaori Yoriki; Shiori Umemura; Kyoko Akashi; Jo Kitawaki

doi:10.18632/oncotarget.9151

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Anti-tumor effect of estrogen-related receptor alpha knockdown on uterine endometrial cancer

Hiroshi Matsushima, Taisuke Mori _, Fumitake Ito, Takuro Yamamoto, Makoto Akiyama, Tetsuya Kokabu, Kaori Yoriki, Shiori Umemura, Kyoko Akashi and Jo Kitawaki

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:34131-34148. https://doi.org/10.18632/oncotarget.9151

Metrics: PDF 2545 views | HTML 3114 views | ?

Abstract

Hiroshi Matsushima1, Taisuke Mori1, Fumitake Ito1, Takuro Yamamoto1, Makoto Akiyama1, Tetsuya Kokabu1, Kaori Yoriki1, Shiori Umemura1, Kyoko Akashi1 and Jo Kitawaki1

1 Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kajii-cho, Kamigyo-ku, Kyoto, Japan

Correspondence to:

Taisuke Mori, email:

Keywords: apoptosis, cell cycle arrest, ERRα, VEGF, uterine endometrial cancer

Received: December 24, 2015 Accepted: April 16, 2016 Published: May 03, 2016

Abstract

Estrogen-related receptor (ERR)α presents structural similarities with estrogen receptor (ER)α. However, it is an orphan receptor not binding to naturally occurring estrogens. This study was designed to investigate the role of ERRα in endometrial cancer progression. Immunohistochemistry analysis on 50 specimens from patients with endometrial cancer showed that ERRα was expressed in all examined tissues and the elevated expression levels of ERRα were associated with advanced clinical stages and serous histological type (p < 0.01 for each). ERRα knockdown with siRNA suppressed angiogenesis via VEGF and cell proliferation in vitro (p < 0.01). Cell cycle and apoptosis assays using flow cytometry and western blot revealed that ERRα knockdown induced cell cycle arrest during the mitotic phase followed by apoptosis initiated by caspase-3. Additionally, ERRα knockdown sensitized cells to paclitaxel. A significant reduction of tumor growth and angiogenesis was also observed in ERRα knockdown xenografts (p < 0.01). These findings indicate that ERRα may serve as a novel molecular target for the treatment of endometrial cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9151

Publication Alerts

Research Papers:

Anti-tumor effect of estrogen-related receptor alpha knockdown on uterine endometrial cancer

Abstract